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Introduction
!
Radiation therapy has an important role in the
treatment of locally advanced or metastatic pan-
creatic cancer and can be used alone or in con-
junction with surgery and/or systemic chemo-
therapy. A major challenge for radiation therapy
is respiratory organ motion. Fiducial markers can
be used for tracking respiration to accurately
measure the extent of target motion. These fidu-
cials can be used for localization and are implan-
ted at the tumor site as reference points to assist
in targeting radiation beams. Fiducials can be
placed surgically or percutaneously under ultra-
sound or computed tomography guidance or by
endoscopic ultrasound (EUS). EUS, a minimally
invasive approach, provides excellent visualiza-
tion of the pancreas and therefore has been used
for endoscopic placement of fiducials in pancreat-
ic lesions. EUS-guided fiducial placement has
been reported for mediastinal tumors, prostate
cancer, and gastrointestinal malignancies, includ-
ing pancreatic cancers, hepatic malignancies, cho-
langiocarcinomas, as well as esophageal, gastric
and colon cancers [1–6]. However, this review fo-
cuses on EUS-guided fiducial placement for the
treatment of pancreatic cancer, which is most rel-
evant to practicing gastroenterologists and inter-
ventional endoscopists.
Treatment of pancreatic cancer
!
Pancreatic adenocarcinoma is the second most
common gastrointestinal malignancy and the
sixth leading cause of cancer mortality in the Uni-
ted States [7]. The prognosis for patients with
pancreatic cancer is poor with an overall five-
year survival rate of 6%. Although surgical resec-
tion can be curative, approximately 20% of pa-
tients are eligible for surgery at diagnosis because
most patients present with locally advanced, in-
operable disease where chemoradiation plays a
role in neoadjuvant therapy, adjuvant treatment,
or palliation. EUS provides important information
about disease stage, including involvement of the
vasculature and adjacent organ invasion, and re-
gional lymph node metastasis. In addition, EUS is
considered the procedure of choice for tissue di-
agnosis of pancreatic cancer. It can be used for
therapeutic interventions such as fine-needle in-
jection, biliary drainage, celiac plexus block or
neurolysis, brachytherapy, fiducial placement,
and emerging therapies with antitumor agents
delivered directly into the tumor [8,9].
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Radiation therapy has an important role in the
treatment of locally advanced or metastatic pan-
creatic cancer and can be used alone or in con-
junction with surgery and/or systemic chemo-
therapy. Because of the challenge of delivering an
accurate and optimal radiation dose, image-guid-
ed radiation therapy can be used to improve tar-
geting. Fiducial markers can be placed in the tu-
mor and used for localization in patients under-
going image-guided radiation therapy. The safety
and feasibility of endoscopic ultrasound (EUS)-
guided placement of fiducials has been assessed
and reported for the management of pancreatic
cancer. We herein review the technique, efficacy,
and safety profile of EUS-guided fiducial place-
ment. In addition, we highlight recent advances
and technological upgrades in EUS-guided fidu-
cial delivery systems for pancreatic cancer most
relevant to practicing gastroenterologists and in-
terventional endoscopists.
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Aggressive local treatment of pancreatic cancer leads to im-
proved local control, which can increase overall survival [10].
For patients with locally advanced pancreatic cancer, chemora-
diation enhances survival rates over chemotherapy alone [11,
12]. Several studies have demonstrated that aggressive local
therapy with radiation dose escalation can improve local control.
Radiation dose escalation has been attempted by way of intraop-
erative radiotherapy, stereotactic body radiotherapy, and intensi-
ty-modulated radiotherapy (IMRT) [13–15]. IMRT provides high-
precision radiotherapy using a computer-controlled linear accel-
erator to deliver precise radiation doses to specific areas while
maintaining or reducing healthy tissue exposure [16]. Image-
guided radiotherapy (IGRT) is a novel technique that uses ad-
vanced imaging technology to verify target position before and
during radiotherapy, and allows the delivery of precisely aimed
radiation beams to tumors [17]. IGRT ensures that IMRT is deliv-
eredwith optimal accuracy. IGRT relies on fiducial markers to tar-
get and track the location of the tumor in real time to ensure that
radiation treatment is delivered to the tumor with pinpoint accu-
racy. The use of fiducial markers has become a viable option to fa-
cilitate accurate delivery of external beam radiation to a patient’s
treatment site during IMRT and IGRT treatments. This advance-
ment in radiation therapy technique improves the chance of sec-
ondary resection, enhances local control for unresectable dis-
ease, and reduces symptoms related to local progression. In clin-
ical practice, the decision for use of EUS-guided fiducial place-
ment and IGRT is made jointlywith oncologists, surgeons, and ra-
diation oncologists.
Fiducial markers
!
Fiducial markers are radiopaque spheres, coils, or seeds that are
implanted into the target lesion in the pancreas for both localiz-
ing and tracking during radiotherapy (). These markers facilitate
safe and accurate targeting of the tumor. Various types of fiducial
markers and delivery systems (●" Fig.1a,b) have been developed
[18]. A minimum of one to two fiducial markers are required to
be placed either within the target lesion or within 1cm of a small
target lesion. Fiducial markers can be placed intraoperatively,
percutaneously, or endoscopically [19,20]. Given the excellent
visualization of lesions in proximity to the gastrointestinal
tract, EUS offers an improved approach for fiducial placement
(●" Fig.2). A higher ideal fiducial geometry for appropriate
tracking has been reported with EUS when compared to sur-
gery [21].
1.Technique
Fiducials can be delivered with 19–or 22-gauge needles, or via
multi-fiducial delivery systems [2,3,5,21–31]. The technique
for fine-needle injection of fiducials is similar to that for fine-
needle aspiration [22]. Traditional fiducials are cylindrical gold
seeds, measuring 3 to 5mm long and 0.75 to 1.2mm in diameter.
The new smaller and longer fiducial markers are 10mm long and
0.28 or 0.35mm in diameter. These new fiducials are available
preloaded on a needle carrier delivery device for use with a 22-
gauge needle [5,29]. Comparative analysis of traditional fiducials
vs coiled fiducials for pancreatic cancer using both 19-gauge and
22-gauge needles via EUS reported higher visibility for tradition-
al fiducials without a difference in fiducial migration [23]. A 19-
gauge needle has been traditionally used, although a 22-gauge
needle has also demonstrated feasibility, safety, and accuracy [5,
24]. A 22-gauge needle is potentially advantageous over a 19-
gauge needle because of its greater flexibility and smaller diame-
ter, particularly when used in challenging anatomic locations or
postsurgical anatomy.
Fiducial placement in the needle.
There are two basic techniques by which the fiducial marker can
be loaded into the EUS needle. The most common technique em-
ployed is the back-loading method [25]. The stylet of the needle
is withdrawn approximately 2–3cm. The fiducial delivery sys-
tem, typically consisting of a fiducial marker loaded on a needle
carrier, is then inserted “retrograde” into the needle tip (●" Fig.3).
The fiducial is then deployed into the needle tip by removing the
needle carrier. Finally, the tip of the EUS needle is plugged or
sealed with a small amount of sterile bone wax to prevent inad-
vertent loss of the fiducial while advancing the needle down the
accessory channel. A new variation of this method is the “wet-fill
technique” where the EUS needle is submerged in sterile saline
and the stylet is slowly retracted approximately 10cm. This effec-
Fig.1 Fiducial markers and a delivery needle.
Fig.2 Fluoroscopic
view of the echoendo-
scope in a long position
with four fiducials
successfully deployed.
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tively fills the distal end of the EUS needle with fluid [24], and the
fiducial marker is then back-loaded into the EUS needle as pre-
viously described. Bone wax is not required to seal the needle
tip because the fiducial is held in place within the needle via the
surface tension of the saline. This technique may have potential
advantages of avoiding failure of deployment related to bone
wax and possible complication of granuloma formation following
implantation of bone wax into tissue [26]. A potential disadvan-
tage to using this back-loadingmethod is the possibility of needle
stick injuries. This is of particular concern when one EUS needle
is reloaded between fiducial deployments. A solution to this
problem is to have multiple preloaded needles readily available.
Recently, the BNX needle aspiration system (Covidien, Dublin,
Ireland) has been introduced for EUS fine-needle aspiration and
EUS-guided fiducial placement (●" Fig.4) [24]. It is engineered to
improve clinical workflow by facilitating the passage of multiple
needles through a single delivery system without removing the
delivery system between needle passages. It allows rapid ex-
change of the needles while keeping the needle sheath and cath-
eter in the echoendoscope. Therefore, having two or three pre-
loaded needles can allow rapid deployment of multiple fiducials
(this system allows placement of multiple fiducials through a sin-
gle delivery system).
Another potential less risky approach to load the EUS needle is by
using an antegrade or front-loading approach [27]. In this meth-
od, the stylet is removed entirely from the EUS needle. The nee-
dle tip is plugged with bone wax. A fiducial marker is then de-
ployed into the top of the needle. The stylet is then reinserted
and slowly advanced, thereby pushing the fiducial into the distal
end of the needle tip.An advantage of this technique is that nee-
dle loading can be performed once the needle has been inserted
into the target lesion. This precludes the need for plugging the tip
with bone wax, and can allow for rapid deployment of multiple
fiducials while the EUS needle is already in the echoendoscope.
Fiducial deployment.
Regardless of the method chosen to load the needle, all fiducials
are typically deployed by advancing the stylet in the needle chan-
nel and pushing the stylet out of the needle tip.
2.Efficacy
EUS evaluation of pancreatic cancer has been reported as an in-
dependent predictor of improved survival in patients with locally
advanced pancreatic cancer [28]. EUS-guided placement of fidu-
cial markers before targeted radiation therapy is a novel clinical
application for cancer management [8,9]. EUS-guided fiducial
placement provides the advantage of being performed during
the same session as EUS examination for staging. In 2006, Pish-
vaian et al. published the first report in which fiducials were suc-
cessfully placed via EUS guidance in six of seven pancreatic can-
cer patients [26]. Sanders and colleagues reported a success rate
of 90% for EUS-guided fiducial placement in 51 patients [29].
These authors used a 19-gauge needle with a pushing stylet tech-
nique for fiducial insertion. They noted difficulty in fiducial
placement in patients who had undergone a prior pancreatico-
duodenectomy. Park et al. reported an 88% success rate of EUS-
guided gold fiducial insertion in 57 patients [30]. These authors
back-loaded the fiducials into a 19-gauge needle and fixed the fi-
ducials to the tip of the needle with bone wax. A sterile water in-
jection techniquewas used to insert the fiducials instead of push-
ing with a stylet. This technique was employed to prevent coiling
of the fiducials. In summary, the feasibility of EUS-guided fiducial
placement with or without fluoroscopy for locally advanced and
recurrent pancreatic cancer has been reported with technical
Fig.3 Needle with fiducial marker.
Fig.4 The BNX needle aspiration system.
Table 1 Efficacy and safety of endoscopic ultrasound-guided fiducial placement.
Study Patients (#) Cancer (type) Efficacy (%) Adverse events (# of patients)
Pishvaian AC et al. [3] 13 Mediastinal and abdominal malignancies 84.6 Infectious complication (1)
Varadarajulu S et al. [31] 9 Pancreatic cancer 100 None
Ammar T et al. [27] 13 Abdominal malignancies 100 None
Park WG et al. [30] 57 Pancreatic cancer 94 Needle malfunction (1), and minor
bleeding (1)
Sanders MK et al. [29] 51 Pancreatic cancer 90 Mild pancreatitis (1)
DiMaio CJ et al. [5] 30 Gastrointestinal malignancies 97 Infectious complication (1)
Choi JH et al. [2] 32 Pancreatic and hepatic malignancy 100 Mild pancreatitis (1)
Majumder S et al. [21] 77 Pancreatic cancer 90 Abdominal pain (3), vomiting (1),
mild pancreatitis (1)
Davila Fajardo R et al. [32] 23 Pancreatic cancer 100 Minor bleeding (1)
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success rates of 85% to 100% [2,3,5,21,27,29–32]. The reported
data on efficacy and safety of EUS-guided fiducial placement are
shown in the●" Table1.
3.Technical difficulties
The use of multiple fiducials can reduce the impact of organ de-
formation and fiducial migration during radiotherapy. Multiple
needle insertions of a single fiducial delivery system are required
to deliver multiple fiducials. Delivery of multiple fiducials re-
quires removal of the needle and manual reloading of each fidu-
cial. It is therefore desirable to provide multiple fiducials in a sin-
gle needle that can be introduced in a single pass and in a con-
trolled serial manner. This would help overcome the difficulties
in advancing fiducials with the echoendoscope in the duodenum
where sharp angulation and torque are needed to target pancre-
atic head and uncinate lesions.
As therapeutic applications of EUS continue to expand, improved
accessories are required to meet treatment needs. It is important
to consider the development of flexible multi-fiducial delivery
needles that can deploy multiple fiducials in one pass. A new
multi-fiducial delivery system that has been recently introduced
is a 22-gauge needle with a holding chamber at the needle tip
preloaded with four gold fiducials and adjustable locking handle.
Each goldmarker is 5mm long. The flexible sheath of the delivery
needle has a 5.2-French outer diameter compatible with the ac-
cessory channel of an echoendoscope [33]. We recently reported
that this delivery system provided quick, easy, and accurate fidu-
cial deployment without adverse events in a live porcine model
[33]. Our human study is currently enrolling patients with pan-
creatic cancer for further evaluation of this new delivery system.
4.Adverse events
Reported complications include acute pancreatitis, minor bleed-
ing, fever, vomiting, abdominal pain, and elevated liver enzymes
[2,3,5,21,29,30,32] as shown in the ●" Table1. Some authors
have suggested use of prophylactic antibiotics [27] during EUS-
guided fiducial placement and further studies are needed to vali-
date this recommendation. The rate of fiducial migration is rela-
tively low (7%) and no migration-related complications have
been reported [29].
5.Future directions
The primary drawback of EUS-guided fiducial placement is the
lack of dedicated accessories designed specifically for fiducial
placement. Multi-fiducial delivery systems are therefore a wel-
come upgrade in this field. More flexible fiducial delivery
systems that are unlikely to bend or kink during deployment
with the echoendoscope in the long position, or in an angulated
and torqued configuration, are desirable to allow fiducial place-
ment in the pancreatic head and uncinate. Enhanced visualiza-
tion of the needle and fiducial during EUS is necessary to allow
fiducial placement solely under endosonographic guidancewith-
out the use of fluoroscopy, thus minimizing radiation exposure
(●" Fig.5). Increasing the awareness of this application of EUS
among oncologists, radiation oncologists, surgeons, gastroenter-
ologists, and interventional endoscopists is vital as this technolo-
gy can become an essential part of the multidisciplinary ap-
proach to pancreatic cancer treatment.
Conclusion
!
Application of image-guided radiation therapy to locally ad-
vanced unresectable pancreatic cancer requires the use of fidu-
cials to track the precise location of the tumor. Fiducial placement
under EUS guidance has been reported as safe, feasible, and effec-
tive. Recent advances in endoscopic accessories for EUS-guided
fiducial placement are promising and will allow more endosco-
pists to adopt this modality in their therapeutic EUS armamen-
tarium.
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